ReviewBMC medicine2016
Cognitive remission: a novel objective for the treatment of major depression?
Review in BMC medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05625230 (Testing the Efficiency of a Psychological Treatment for the Rehabilitation of Action Cognition in Depression), which is not on this map. Cited by 97 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Testing the Efficiency of a Psychological Treatment for the Rehabilitation of Action Cognition in Depression
Who cites it
97 citing papers in PubMed, 5 syntheses or guidelines pooled it, 244 citations in OpenAlex.
- The Impact of Citicoline/Phosphatidylserine Supplementation on Cognitive Performance and Executive Functions in Mental Disorders: A Systematic Review of Controlled Trials.Human psychopharmacology · 2026Pooled it
- Change in Cognitive Function over the Course of Major Depressive Disorder: A Systematic Review and Meta-analysis.Neuropsychology review · 2025Pooled it
- Biomarkers of neuroprogression and late staging in bipolar disorder: A systematic review.The Australian and New Zealand journal of psychiatry · 2023Pooled it
- Evidence-based umbrella review of cognitive effects of prefrontal tDCS.Social cognitive and affective neuroscience · 2022Pooled it
- Imaging genetics paradigms in depression research: Systematic review and meta-analysis.Progress in neuro-psychopharmacology & biological psychiatry · 2018Pooled it
- Effects of virtual reality eye movement desensitization and reprocessing therapy for adolescents with major depressive disorder: a functional Near-Infrared spectroscopy study.European child & adolescent psychiatry · 2026Trial
- Real-World Effects of Home-Based Transcranial Direct Current Stimulation in Depression: A Randomized Controlled Trial of 3-Week Versus 6-Week Protocols.Brain and behavior · 2025Trial
- A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality.Neuropsychiatric disease and treatment · 2024Trial
- Trial
- Antiviral treatment perspective against Borna disease virus 1 infection in major depression: a double-blind placebo-controlled randomized clinical trial.BMC pharmacology & toxicology · 2020Trial
- Assessing biological pathways in the longitudinal association between neighborhood environment and depressive symptoms.Journal of affective disorders · 2026Article
- No Cognitive Scarring Over 20 Years in Recurrent Depression: Bidirectionality of Cognitive Functioning and Depression.Clinical psychology in Europe · 2026Article
- Cognitive impairment and associated factors among patients with mood disorders receiving care at public hospitals in Gedeo zone, Southern Ethiopia.Social psychiatry and psychiatric epidemiology · 2026Article
- Bidirectional causal association between frailty and six psychiatric disorders.European archives of psychiatry and clinical neuroscience · 2026Article
- Relationships of oxidative stress, inflammation and gut microbiota with cognitive impairment in first-episode major depressive disorders: a pilot study in China.Frontiers in microbiology · 2026Article
- Connectome Gradient-Based Subtyping of Major Depressive Disorder Reveals Distinct Neurobiological and Transcriptomic Signatures.Depression and anxiety · 2026Article
- The relationship between cognitive impairment and acoustic features in major depressive disorder: a longitudinal cohort study.BMC psychiatry · 2025Article
- Network analysis of the relationships among activities of daily living disability, cognitive impairment, and depression in Chinese older adults.BMC public health · 2025Article
- The correlation between high temperature and cognitive function: a CHARLS 2018 cross-sectional study.Archives of public health = Archives belges de sante publique · 2025Article
- Aberrant brain dynamics in major depressive disorder during working memory task.European archives of psychiatry and clinical neuroscience · 2025Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCognitive dysfunction in major depressive disorder (MDD) encompasses several domains, including but not limited to executive function, verbal memory, and attention. Furthermore, cognitive dysfunction is a frequent residual manifestation in depression and may persist during the remitted phase. Cognitive deficits may also impede functional recovery, including workforce performance, in patients with MDD. The overarching aims of this opinion article are to critically evaluate the effects of available antidepressants as well as novel therapeutic targets on neurocognitive dysfunction in MDD. DISCUSSION: Conventional antidepressant drugs mitigate cognitive dysfunction in some people with MDD. However, a significant proportion of MDD patients continue to experience significant cognitive impairment. Two multicenter randomized controlled trials (RCTs) reported that vortioxetine, a multimodal antidepressant, has significant precognitive effects in MDD unrelated to mood improvement. Lisdexamfetamine dimesylate was shown to alleviate executive dysfunction in an RCT of adults after full or partial remission of MDD. Preliminary evidence also indicates that erythropoietin may alleviate cognitive dysfunction in MDD. Several other novel agents may be repurposed as cognitive enhancers for MDD treatment, including minocycline, insulin, antidiabetic agents, angiotensin-converting enzyme inhibitors, S-adenosyl methionine, acetyl-L-carnitine, alpha lipoic acid, omega-3 fatty acids, melatonin, modafinil, galantamine, scopolamine, N-acetylcysteine, curcumin, statins, and coenzyme Q10. The management of cognitive dysfunction remains an unmet need in the treatment of MDD. However, it is hoped that the development of novel therapeutic targets will contribute to 'cognitive remission', which may aid functional recovery in MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.